DE69840962D1 - Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel - Google Patents

Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel

Info

Publication number
DE69840962D1
DE69840962D1 DE69840962T DE69840962T DE69840962D1 DE 69840962 D1 DE69840962 D1 DE 69840962D1 DE 69840962 T DE69840962 T DE 69840962T DE 69840962 T DE69840962 T DE 69840962T DE 69840962 D1 DE69840962 D1 DE 69840962D1
Authority
DE
Germany
Prior art keywords
adjuvant
compositions
polysorbate
cyclodextrin
aid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840962T
Other languages
English (en)
Inventor
Charlotte Kensil
Gerald A Beltz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenus Inc
Original Assignee
Antigenics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigenics LLC filed Critical Antigenics LLC
Application granted granted Critical
Publication of DE69840962D1 publication Critical patent/DE69840962D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
DE69840962T 1997-08-29 1998-08-28 Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel Expired - Lifetime DE69840962D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725597P 1997-08-29 1997-08-29
PCT/US1998/017940 WO1999010008A1 (en) 1997-08-29 1998-08-28 Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient

Publications (1)

Publication Number Publication Date
DE69840962D1 true DE69840962D1 (de) 2009-08-20

Family

ID=22009474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840962T Expired - Lifetime DE69840962D1 (de) 1997-08-29 1998-08-28 Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel

Country Status (10)

Country Link
US (2) US6645495B1 (de)
EP (2) EP1009429B1 (de)
JP (3) JP5220248B2 (de)
AT (1) ATE435661T1 (de)
AU (1) AU734180B2 (de)
CA (2) CA2654522C (de)
DE (1) DE69840962D1 (de)
ES (2) ES2327693T3 (de)
HK (1) HK1129846A1 (de)
WO (1) WO1999010008A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010008A1 (en) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
EP1104306B1 (de) * 1998-08-10 2006-01-11 Antigenics Inc. Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
AU5793600A (en) * 1999-09-22 2001-03-29 Baker Hughes Incorporated Hydraulic fracturing using non-ionic surfactant gelling agent
US8017590B1 (en) 1999-10-22 2011-09-13 Sanofi Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1282702B1 (de) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
PL211151B1 (pl) 2000-10-18 2012-04-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002218535A8 (en) * 2000-12-12 2008-01-17 Japan Tobacco Inc Pharmaceutical composition containing an active with a hemolytic action and a surfactant
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004037189A2 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1687022A4 (de) 2003-11-12 2008-02-13 Medical Res Council Renta: hiv-immunogen und seine anwendungen
ATE491467T1 (de) 2004-05-28 2011-01-15 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006055875A2 (en) * 2004-11-18 2006-05-26 University Of Rochester Methods and compositions related to esculentoside a
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US7622121B2 (en) * 2005-09-21 2009-11-24 New York University Heat shock proteins from Mycobacterium leprae and uses thereof
EP1965856A2 (de) 2005-12-30 2008-09-10 Tti Ellebeau, Inc. Iontophoretische systeme, vorrichtungen und verfahren zur abgabe von wirkstoffen an eine biologische schnittstelle
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2007143606A2 (en) 2006-06-02 2007-12-13 International Aids Vaccine Initiative Hiv-1 clade a consensus sequences, antigens, and transgenes
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2007354917B2 (en) 2006-09-26 2013-06-06 Access To Advanced Health Institute Vaccine composition containing synthetic adjuvant
LT2137210T (lt) 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Naujas būdas ir kompozicijos
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
KR101540920B1 (ko) * 2007-07-26 2015-08-03 사노피 파스퇴르 리미티드 항원-애주번트 조성물 및 방법
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2062594A1 (de) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Impfstoff und immunogene Zusammensetzung gegen den Blauzungenvirus, Verfahren zu deren Verwendung und Verfahren zu deren Herstellung
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EP2442827B1 (de) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsionsimpfstoffe
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
MY157607A (en) * 2009-09-10 2016-06-30 Merial Inc New vaccine formulations comprising saponin-containing adjuvants
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EP2701736A1 (de) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Trunkierte hiv-hüllproteine (env), verfahren und zugehörige zusammensetzungen
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
PE20141547A1 (es) 2011-09-16 2014-10-25 Ucb Pharma Sa Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
JP6121436B2 (ja) 2011-11-23 2017-04-26 バイオベン・3・リミテッドBioven 3 Limited 組換えタンパク質及びそれらの治療的用途
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
EP2892555B1 (de) 2012-09-10 2020-03-25 International Aids Vaccine Initiative Immunogene aus breit neutralisierenden hiv-1-antikörpern, verfahren zur herstellung und verwendungen davon
MY187936A (en) 2013-03-15 2021-10-29 In3Bio Ltd Self-assembling synthetic proteins
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015063611A2 (en) 2013-11-01 2015-05-07 University Of Oslo Albumin variants and uses thereof
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
BR112016015422A2 (pt) 2013-12-31 2017-10-24 Infectious Disease Res Inst formulações de vacina de frasco único
JP6458809B2 (ja) 2014-04-25 2019-01-30 味の素株式会社 免疫賦活剤
WO2015171975A1 (en) 2014-05-09 2015-11-12 The Regents Of The University Of Michigan Use of modified banana lectin in purification of glycoproteins
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
JP7158853B2 (ja) 2014-10-10 2022-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
WO2016141320A2 (en) 2015-03-05 2016-09-09 Northwestern University Non-neuroinvasive viruses and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
AU2016260540B2 (en) 2015-05-13 2021-01-07 Agenus Inc. Vaccines for treatment and prevention of cancer
BR112018003186A2 (pt) 2015-09-01 2018-09-25 Agenus Inc. anticorpos anti-pd-1 e seus métodos de uso
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
EP3368508A1 (de) 2015-10-28 2018-09-05 Ajinomoto Co., Inc. Immunstimulierendes mittel
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
TN2018000301A1 (en) 2016-03-14 2020-01-16 Univ Oslo Engineered immunoglobulins with altered fcrn binding
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
BR112019014510A2 (pt) 2017-01-13 2020-02-18 Agenus Inc. Receptores de célula t que se ligam ao ny-eso-1 e métodos de uso dos mesmos
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
PL3618863T3 (pl) 2017-05-01 2023-11-06 Agenus Inc. Przeciwciała anty- tigit i sposoby ich zastosowania
IL300235A (en) 2017-07-18 2023-03-01 In3Bio Ltd Synthetic proteins and their therapeutic uses
SG11202001319QA (en) 2017-09-04 2020-03-30 Agenus Inc T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
EP3678699A1 (de) 2017-09-07 2020-07-15 University Of Oslo Impfstoffmoleküle
US20220118076A1 (en) 2017-09-07 2022-04-21 University Of Oslo Vaccine molecules
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
AU2019277361A1 (en) 2018-05-30 2020-12-17 Translate Bio, Inc. Messenger RNA vaccines and uses thereof
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
TW202102256A (zh) 2019-03-05 2021-01-16 比利時商葛蘭素史密斯克藍生物品公司 B型肝炎免疫法及組合物
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
KR20220058527A (ko) 2019-06-25 2022-05-09 인3바이오 리미티드 안정화된 키메라 합성 단백질 및 그 치료 용도
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US20210338804A1 (en) 2020-02-21 2021-11-04 International Aids Vaccine Initiative Inc. Vaccine Compositions For Preventing Coronavirus Disease
WO2021177248A1 (ja) 2020-03-02 2021-09-10 株式会社シクロケムバイオ 腸管機能向上剤
MX2023006320A (es) 2020-12-02 2023-06-14 Glaxosmithkline Biologicals Sa Cadena donante complementada fimh.
WO2022207793A1 (en) 2021-03-31 2022-10-06 Vib Vzw Vaccine compositions for trypanosomatids

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3446515A1 (de) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg Oeladjuvierte vaccine und verfahren zu ihrer herstellung
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
ZA872532B (en) * 1986-04-21 1987-11-25 Akzo Nv Combined vaccine
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
ZA927037B (en) * 1991-09-30 1993-03-29 Akzo Nv Respiratory disease vaccine for cats.
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
JP2510943B2 (ja) * 1993-06-07 1996-06-26 株式会社ドクターマインツ 痩身用食品
EP0724433B1 (de) * 1993-10-22 1998-12-30 Genentech, Inc. Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
KR0184779B1 (ko) * 1995-04-13 1999-04-01 성재갑 퀼라야 사포나리아 몰리나로부터 분리정제된 사포닌 변이체, 이의 분리정제 방법 및 이를 함유하는 백신 제형
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
EP0996451B1 (de) * 1997-05-20 2005-01-05 Galenica Pharmaceuticals, Inc. Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
WO1999010008A1 (en) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient

Also Published As

Publication number Publication date
JP2011162559A (ja) 2011-08-25
HK1129846A1 (en) 2009-12-11
WO1999010008A1 (en) 1999-03-04
JP2001513575A (ja) 2001-09-04
CA2302522A1 (en) 1999-03-04
ES2327693T3 (es) 2009-11-02
ATE435661T1 (de) 2009-07-15
CA2654522C (en) 2014-01-28
CA2302522C (en) 2010-08-17
ES2500490T3 (es) 2014-09-30
EP1009429B1 (de) 2009-07-08
JP5220248B2 (ja) 2013-06-26
EP2050465A2 (de) 2009-04-22
US20050191310A1 (en) 2005-09-01
EP2050465A3 (de) 2009-09-02
EP1009429A1 (de) 2000-06-21
AU9210798A (en) 1999-03-16
AU734180B2 (en) 2001-06-07
EP2050465B1 (de) 2014-06-11
CA2654522A1 (en) 1999-03-04
US6645495B1 (en) 2003-11-11
JP2009197014A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
ATE435661T1 (de) Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
PT770397E (pt) Vacina de combinacao contra o virus da doenca de newcastle
HK1046016B (zh) 疫苗中的重組脫氧核糖核酸膠原
BR9910973A (pt) Vacina
BR9107206A (pt) Processo para produzir uma variante de proteina que evoca uma resposta imunogenica diminuida em animais,produtos obtidos,composicao e uso
ATE146360T1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
DK0910406T3 (da) Rekombinante hunde-herpesvirus
GR3032543T3 (en) Signal transmission and tag power consumption measurement circuit for an inductive reader.
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
DE69828801D1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
DE69614390T2 (de) Antiwachstumwirksame proteine aus oozyten von rana pipiens
ES2096727T3 (es) Productos cosmeticos y farmaceuticos que contienen extensinas.
ES2119779T3 (es) Solubilizacion de proteinas en formas activas.
ES2170144T3 (es) Variantes que no se empalman de gp350/220.
DK0588177T3 (da) Interferon-alpha/beta-bindende protein, fremstilling heraf samt farmaceutiske præparater indeholdende proteinet
NO942323L (no) Soyaprotein eller hydrolysater i farmasöytiske preparater for beskyttelse av bioaktive peptider mot enzymatisk inaktivering
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
PT97584A (pt) Processo para a preparacao de composicoes farmaceuticas que contem eritropolietina
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
FR2559157B1 (fr) Nouvel hexapeptide, son procede d'obtention et les compositions pharmaceutiques qui le contiennent
DE69130953D1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
IT1153208B (it) Procedimento per l'estrazione di sostanze azotate, in particolare proteine e/o amminoacidi da sostanze vegetali, in particolare da sottoprodotti della lavorazione della soia

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ANTIGENICS INC., LEXINGTON, MASS., US

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: JONES DAY RECHTSANWAELTE PATENTANWAELTE, 80538 MUE

8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT